Access to medicine, clinical trials, product quality, falsified medicine
- Every person has a right to the highest attainable standard of mental and physical health.
- The Novartis Access Principles are reflective of the United Nations (UN) Availability, Accessibility, Acceptability, and Quality (AAAQ) framework, developed by the UN Committee on Economic, Social and Cultural Rights. Novartis implements global strategies, ethical practices, and sustainable solutions to ensure its health products and services reach and benefit underserved populations.
- In 2024, we ranked first in the 2024 Access to Medicine Index (ATMI), reflecting our leadership in research, development and improving access to medicines around the world.
- We aim to extend our impact by:
- Making our products as accessible as possible around the world while maintaining the sustainability of our business. Please see here how we systematically integrate access strategies.
- Conducting and monitoring clinical trials in accordance with international human rights standards that protect patients’ rights and safety.
- Producing the highest quality medicine in strict compliance with Good Manufacturing Practice, as certified by regulatory bodies.
- Monitoring, authenticating and reporting incidents of falsified medicines.
- For more details on our overall Global Health program, click here.